Eli Lilly & Co. (NYSE: LLY) CEO John Lechleite says there's no concern about the company's dividend, according to CNBC.

David A. Ricks. Senior Vice President and President, Lilly Bio-Medicines, also added that investors want the company to continue exploring solutions for Alzheimer's disease.

Dividends Trader Talk

Eli Lilly (LLY) PT Cut to $92 at Leerink PartnersNovember 23, 2016 2:57 PM BMO Capital Downgrades Eli Lilly (LLY) to Market Perform Following Sola's FailureNovember 23, 2016 1:48 PM Eli Lilly & Co. (LLY) AD Portfolio Uncertain Following Sola Failure - LeerinkNovember 23, 2016 7:48 AM Eli Lilly & Co. (LLY) Sinks 11% on Solanezumab FailureNovember 23, 2016 6:54 AM Biogen (BIIB) Trades Lower on Eli Lilly (LLY) Solanezumab FailureNovember 23, 2016 6:52 AM Eli Lilly & Co. (LLY) volatility elevated into Alzheimer's data November 23, 2016 6:51 AM Eli Lilly & Co. (LLY) Announces Solanezumab Phase 3 in Alzheimer's Disease Missed Primary EndpointNovember 23, 2016 6:45 AM